Table 1.
Impact of resveratrol on the expression of genes in the context of cardiovascular disorders
| Type of disease | Dose range | Cell line | Target | Pathway | Function | Refs. |
|---|---|---|---|---|---|---|
| In vivo studies | ||||||
| Cardiac Hypertrophy | 30 mg/kg | – | Bax, Bcl-2, Beclin-1, p62 | PI3K/AKT/mTOR | RVT by targeting the PI3K/AKT/mTOR pathway could prevent chronic intermittent hypoxia-induced cardiac hypertrophy | [14] |
| Cardiovascular Diseases | 15 mg/kg | – | SIRT1, FOXO3, Fas, FADD, Caspase-3/8, Sirt-1, BNP, TNF-α, PARP | PI3K/AKT | RVT via synergetic activation of PI3K/AKT and SIRT1signaling could improve the beneficial effects of exercise training in aging rat hearts | [15] |
| Heart Failure (HF) | 2.5 mg/kg | – | Caspase-3, Serca2a, PLB | PI3K/AKT/eNOS | RVT via the PI3K/AKT/eNOS pathway could decrease reduces atrial fibrillation susceptibility in HF | [16] |
| In vitro studies | ||||||
| Acute Myocardial Infarction (AMI) | 20 μM | Cardiomyocyte | – | P13K/AKT/e-NOS | RVT via blocking the P13K/AKT/e-NOS pathway could protect cardiomyocyte apoptosis induced by I/R injury in AMI | [17] |